Home Newsfeeds Morgan Stanley Maintains Equal-Weight on Clearwater Analytics Hldg, Lowers Price Target to $14

Morgan Stanley Maintains Equal-Weight on Clearwater Analytics Hldg, Lowers Price Target to $14

Morgan Stanley analyst James Faucette maintains Clearwater Analytics Hldg (NYSE:CWAN) with a Equal-Weight and lowers the price target from $21 to $14.

byBenzinga Newsdesk

July 27, 2022

1 minute read

Morgan Stanley analyst James Faucette maintains Clearwater Analytics Hldg (NYSE:CWAN) with a Equal-Weight and lowers the price target from $21 to $14.

Dow Rises Over 100 Points; Revelation Biosciences Shares Spike Higher

By Lisa Levin

July 25, 12:43 PM

U.S. stocks traded mostly higher midway through trading on Monday.

BORR

Movers
News

SunPower Stock Is Soaring Tuesday: What’s Going On?

By Adam Eckert

May 14, 9:03 AM

SunPower shares are trading higher Tuesday as high short-interest stocks gain amid the return of trader "Roaring Kitty" to social media. Additionally, the Biden administration raised tariffs on Chinese solar panels.

GME

UPDATE: NeoGames Q4 Adj. EPS $0.22 Beats $(0.13) Estimate, Sales $69.22M Miss $75.36M Estimate

By Happy Mohamed

March 6, 5:35 PM

NeoGames (NASDAQ:NGMS) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $(0.13) by 269.23 percent. This is a 257.14 percent increase over losses of $(0.14) per share from the

NGMS

Eli Lilly’s Donanemab Gains Favorable FDA Advisory Verdict, Boosting Stock Potential, Says BofA Analyst

By Nabaparna Bhattacharya

June 11, 2:19 PM

Eli Lilly's donanemab for Alzheimer's disease garners positive FDA committee verdict, prompting analyst's bullish outlook amid comparisons to Biogen's Leqembi.

BIIB

Morgan Stanley Maintains Equal-Weight on Clearwater Analytics Hldg, Lowers Price Target to $14

Related Posts

Dow Rises Over 100 Points; Revelation Biosciences Shares Spike Higher

SunPower Stock Is Soaring Tuesday: What’s Going On?

UPDATE: NeoGames Q4 Adj. EPS $0.22 Beats $(0.13) Estimate, Sales $69.22M Miss $75.36M Estimate

Eli Lilly’s Donanemab Gains Favorable FDA Advisory Verdict, Boosting Stock Potential, Says BofA Analyst